← All trials
NCT00977964
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2009
- Primary completion
- Jan 31, 2010
- Completion date
- Jan 31, 2010
- First posted
- Sep 16, 2009
- Last posted
- Nov 25, 2010
- Enrollment
- 270
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AbbottLead sponsor
- AbbottSponsor investigator
- Case Western Reserve UniversityOverall official - principal investigator
- Case Western Reserve UniversityOfficial
- Dayton Clinical ResearchOfficial
- Alabama Clinical TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.